By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
There are numerous industrial and potential biomedical applications for chitosan. It can be used in agriculture as a biopesticide and seed treatment, assisting plants in warding off fungus infestations. It can be used as a fining agent in winemaking, which also helps to ward off rotting. It can be utilized in self-healing polyurethane paint coatings for industrial use.
It can be used to help distribute medications through the skin and is beneficial in bandages to stop bleeding and as an antibacterial agent in medicine. Because of its capacity to attach to dietary lipids in the digestive system and lessen their absorption, chitosan is marketed as a weight-loss supplement. However, there are still concerns and studies regarding its efficacy as a weight-loss technique.
But research into and debate about its effectiveness as a weight-loss tool continues.It is used in cosmetic and skincare products because of its moisturizing and film-forming properties. It can improve skin texture and act as a barrier. Chitosan has been investigated as a potential component in biodegradable plastics and packaging materials as an environmentally acceptable alternative to traditional polymers.
Since chitosan is a flexible and advantageous material for the environment, it has drawn a lot of interest from a variety of sectors searching for sustainable solutions. Chitosan is a widely used material in the biomedical industry due to its biocompatibility and biodegradability. It is important in wound dressings because it can aid in the encouragement of wound healing and the reduction of infections.
The Brazil Chitosan market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
In Brazil, the University of Brasilia, in collaboration with the University of Campinas, Brazil, Centro de Pesquisa em Biotecnologia Ltda, Hospital Regional da Asa Norte (HRAN), Hospital da Região Leste (HRL), and Hospital Universitário de Brasília (HUB/UnB), was conducting VESTA clinical trial to assess the effectiveness of a novel respirator with chitosan nanoparticles to reduce the incidence of SARS-CoV-2 infection in healthcare professionals.
Novochizol is a novel chitosan nanoparticle technology that can be utilized to transport and limit any prospective anti-COVID-19 medicine to the lungs of critically ill patients. Bioavanta-Bosti is a pioneer in the study of chitosan nanoparticles.
